Last update :
16/06/2024
Various   Eculizumab  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Soliris Argentina, Australia, Belgium, Brazil, Canada, Finland, France, Germany, Great Britain, Hungary, Ireland, Italy, Japan, Luxembourg, Mexico, Norway, Romania, Spain, Switzerland, United States of America
Stability in solutions   Injection   Stability in solutions : Eculizumab     
Container Solvent Concentration Temperature Storage Duration of stability References
Glass Sodium chloride 0,9% 5 mg/ml 2-8°C Not specified
90 Day
4782
Level of evidence A+
Biosimilar
Glass Sodium chloride 0,9% 5 mg/ml 28-32°C Not specified
72 Hour
4782
Level of evidence A+
Biosimilar
Glass Sodium chloride 0,45% 5 mg/ml 2-8°C Not specified
90 Day
4782
Level of evidence A+
Biosimilar
Glass Sodium chloride 0,45% 5 mg/ml 28-32°C Not specified
72 Hour
4782
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,9% 5 mg/ml 2-8°C Not specified
90 Day
4782
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,9% 5 mg/ml 28-32°C Not specified
72 Hour
4782
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,45% 5 mg/ml 2-8°C Not specified
90 Day
4782
Level of evidence A+
Biosimilar
Polyolefine Sodium chloride 0,45% 5 mg/ml 28-32°C Not specified
72 Hour
4782
Level of evidence A+
Biosimilar
Not specified NaCl 0,9% or Glucose 5% 5 mg/ml 2-8°C Not specified
24 Hour
2348
Manufacturer's stability data

Not specified Sodium chloride 0,45% 5 mg/ml 2-8°C Not specified
24 Hour
2348
Manufacturer's stability data


  Mentions Légales